Association between single-nucleotide polymorphisms in Mal/TIRAP and interleukin-10 genes and susceptibility to invasive Haemophilus influenzae serotype b infection in immunized children

Clinical Infectious Diseases

Volumn 51, Issue 7, 2010, Pages 761-767

  Ladhani, Shamez N ^a,b   Davila, Sonia ^d   Hibberd, Martin L ^d   Heath, Paul T ^b   Ramsay, Mary E ^b   Slack, Mary P E ^b   Pollard, Andrew J ^c   Booy, Robert ^a,e  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; INTERLEUKIN 10; PROTEIN; TIRAP PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BACTEREMIA; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; EPIGLOTTITIS; FAMILY; FEMALE; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAEMOPHILUS INFLUENZAE TYPE B; HOMOZYGOSITY; HUMAN; IMMUNE RESPONSE; INFECTION SENSITIVITY; INFLUENZA B; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MENINGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM; VACCINE FAILURE;

BACTERIAL CAPSULES; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; INTERLEUKIN-10; LINKAGE DISEQUILIBRIUM; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MYELIN PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTEOLIPIDS; RECEPTORS, INTERLEUKIN-1; TREATMENT FAILURE;

EID: 77957846970     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656236     Document Type: Article

References (40)

1. Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 2000; 284:2334-2340.
2. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13:302-317.
3. Heath PT, Booy R, Griffiths H, et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis 2000; 31:973-980.
4. McVernon J, Ramsay ME, McLean AR. Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom. Epidemiol Infect 2008; 136:800-812.
5. Ladhani S, Slack MP, Heys M, White J, Ramsay ME. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 2008; 93:665-669.
6. Booy R, Hodgson S, Carpenter L, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994; 344:362-366.
7. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188:481-485.
8. Ladhani S, Heath PT, Aibara RJ, et al. Long-term complications and risk of other serious infections following invasive Haemophilus influenzae serotype b disease in vaccinated children. Vaccine 2010; 28:2195-2200.
9. Ladhani S, Heath PT, Ramsay ME, et al. Long-term immunological follow-up of children with Haemophilus influenzae serotype b vaccine failure in the United Kingdom. Clin Infect Dis 2009; 49:372-380.
10. Ladhani S, Booy R. Host genetic susceptibility to infection. In: Nadel S, ed. Infectious diseases in paediatric intensive care. London: Springer, 2008:225-311.
11. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449:851-861.
12. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-678.
13. Booy R, Hodgson SA, Slack MP, Anderson EC, Mayon-White RT, Moxon ER. Invasive Haemophilus influenzae type b disease in the Oxford region (1985-91). Arch Dis Child 1993; 69:225-228.
14. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
15. Sciacca FL, Ferri C, Licastro F, et al. Interleukin-1B polymorphism is associated with age at onset of Alzheimer's disease. Neurobiol Aging 2003; 24:927-931.
16. Nikolopoulos GK, Dimou NL, Hamodrakas SJ, Bagos PG. Cytokine gene polymorphisms in periodontal disease: a meta-analysis of 53 studies including 4178 cases and 4590 controls. J Clin Periodontol 2008; 35:754-767.
17. Sobti RC, Kordi Tamandani DM, Shekari M, Kaur P, Malekzadeh K, Suri V. Interleukin 1 beta gene polymorphism and risk of cervical cancer. Int J Gynaecol Obstet 2008; 101:47-52.
18. Sakuma K, Uozaki H, Chong JM, et al. Cancer risk to the gastric corpus in Japanese, its correlation with interleukin-1beta gene polymorphism (+3953*T) and Epstein-Barr virus infection. Int J Cancer 2005; 115:93-97.
19. Cox A, Camp NJ, Nicklin MJ, di Giovine FS, Duff GW. An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am J Hum Genet 1998; 62:1180-1188.
20. Bazrafshani MR, Hajeer AH, Ollier WE, Thornhill MH. IL-1B and IL-6 gene polymorphisms encode significant risk for the development of recurrent aphthous stomatitis (RAS). Genes Immun 2002; 3:302-305.
21. Milford Ward A, Sheldon J, Rowbotom A, Wild GD. PRU handbook of clinical immunochemistry. 9th ed. Sheffield: United Kingdom PRU Publications, 2007.
22. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420:329-333.
23. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420: 324-329.
24. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17:1-14.
25. Alexopoulou L, Thomas V, Schnare M, et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in. Nat Med 2002; 8:878-884.
26. Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39:523-528.
27. Castiblanco J, Varela DC, Castano-Rodriguez N, Rojas-Villarraga A, Hincapie ME, Anaya JM. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol 2008; 8:541-544.
28. Sheedy FJ, Marinou I, O'Neill LA, Wilson AG. The Mal/TIRAP S180L and TLR4 G299D polymorphisms are not associated with susceptibility to, or severity of, rheumatoid arthritis. Ann Rheum Dis 2008; 67:1328-1331.
29. Cantaert T, Stone MA, ter Borg M, et al. A functional polymorphism of TIR-domain-containing adaptor protein is not associated with axial spondyloarthritis. Ann Rheum Dis 2008; 67:720-722.
30. Ferwerda B, Alonso S, Banahan K, et al. Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci U S A 2009; 106:10272-10277.
31. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol 2003; 24:254-258.
32. Kenny EF, Talbot S, Gong M, Golenbock DT, Bryant CE, O'Neill LA. MyD88 adaptor-like is not essential for TLR2 signaling and inhibits signaling by TLR3. J Immunol 2009; 183:3642-3651.
33. Ku CL, Picard C, Erdos M, et al. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J Med Genet 2007; 44:16-23.
34. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24:1-8.
35. Zhang X, Hei P, Deng L, Lin J. Interleukin-10 gene promoter polymorphisms and their protein production in peritoneal fluid in patients with endometriosis. Mol Hum Reprod 2007; 13:135-140.
36. Scumpia PO, Moldawer LL. Biology of interleukin-10 and its regulatory roles in sepsis syndromes. Crit Care Med 2005; 33:S468-S471.
37. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008; 121:1108-1111.
38. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002; 30:S58-S63.
39. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177:1205-1208.
40. Rafei K, Lichenstein R. Airway infectious disease emergencies. Pediatr Clin North Am 2006; 53:215-242.